Potential Pediatric Acetaminophen Label Changes Resurface In Tylenol Class Action Settlement
Executive Summary
Settlement could be another milestone in the contentious history of labeling for OTC acetaminophen single-ingredient products generally, and for infant’s and children’s products specifically. Plaintiffs alleged they were misled by J&J to pay more for Infant's Tylenol even though its formulation is the same as Children's Tylenol.
You may also be interested in...
US Recalls: Incorrect Dosing Cups In Robitussin, Dimetapp; Lidocaine Patch GMP Records Lost
GSK recalls two lots of Children's Robitussin DM and one lot of Children's Dimetapp found to include incorrect dosing cups. Chinese firm Bingbing Pharmaceutical recalls 456,760 lidocaine patches due to the loss of product manufacturing records and product samples.
Acetaminophen Dose Labeling, More Sunscreen Information Needed, House Appropriators Tell FDA
Appropriators are "concerned that the lack of dosing information" on OTC drugs for children ages six months to 2 years "may lead to dosing errors, adverse events and inadequate treatment of fever and pain.” They also ask USDA about fraud in its National Organic Program.
Tylenol First To Move On Single Dosage For Children’s Acetaminophen
Johnson & Johnson narrows its pediatric Tylenol tablets a single 160 mg dose and other manufacturers are expected to follow suit, in line with a US FDA panel recommendation.